Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Orforglipron is a once-a-day pill that acts on glucagonlike peptide 1 (GLP-1) receptors
In humans, OCT1 is mainly expressed in the sinusoid membrane of hepatocytes, whereas in rodents, OCT1 is strongly expressed in the basolateral membrane of renal proximal tubule cells
Marketed By
Vilsbll has received personal honoraria for consulting, lectures and/or for advisory board participation within the last 36 months from Amgen, AstraZeneca, Boehringer-Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Merck Sharp & Dohme, Novo Nordisk, Sanofi-Aventis, and Zealand Pharma and has received unrestricted research grants from Novo Nordisk and the Novo Nordisk Foundation
The index dispensing was the first eligible, new-use dispensing during the study period, and the date of this dispensing was the index date
US$ 20.03
US$ 28.72
US$ 22.22
